A new report released Monday by UnitedHealth Group finds that administering specialty drugs—which are typically injected or infused—in homes or in independent physician offices instead of hospitals could save as much as $4 billion each year.
A new report released Monday by UnitedHealth Group finds that administering specialty drugs—which are typically injected or infused—in homes or in independent physician offices instead of hospitals could save as much as $4 billion each year.
The report focused on the 5 conditions—multiple sclerosis (MS), immune deficiency, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and chemotherapy—that account for more than 75% of spending on administered drugs.
Changing the setting of administration would save $16,000 to $37,000 per privately insured patient per year, the report said, reflecting a savings opportunity between 33% and 52%.
By condition, the report separated monthly costs by place of administration:
For 2 conditions—RA and IBD—costs were slightly higher when drugs were administered at home versus a provider’s office, but both sites were still far less than hospital settings.
For chemotherapy, the report found a $16,000 savings for 4 months of treatment ($8281 monthly costs for a provider’s office and $12,315 for a hospital setting).
The report comes as the use of specialty drugs is increasing; since 2013, annual growth in per capita spending on administered specialty drugs has averaged 14%. With healthcare costs expected to reach $6 trillion by 2027, policymakers have been grappling with different ideas to try to reverse the trends.
The report said that treating patients at home could add to physical and mental wellbeing, with fewer schedule disruptions related to work or family, without the likelihood of adverse drug events or side effects.
Compared to independent physician offices, hospitals charge more for specialty drugs and their administration, whether treatment occurs in a hospital or in a hospital-owned physician practice.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.